FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to the field of pharmaceutics, namely to a liquid composition of an antibody against TNF-α and a method for its preparation. The liquid composition contains an antibody against TNF-α, a stabilizer, which is polyol, amino acid other than arginine, or a combination thereof, a surfactant, methionine and arginine in certain concentrations, wherein the liquid composition does not contain an additional buffer. The method for preparation of a liquid composition includes mixing an antibody against TNF-α, a stabilizer, a surfactant, methionine and arginine.
EFFECT: group of inventions provides improved stability of an antibody against TNF-α in a liquid composition containing a stabilizer, a surfactant and arginine, without an additional buffer, due to the addition of an antioxidant – methionine.
13 cl, 18 tbl, 2 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | 2013 |
|
RU2683861C2 |
| STABLE PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2736830C2 |
| STABLE LIQUID PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2773747C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| NEW STABLE COMPOSITIONS FOR FXIA ANTIBODIES | 2018 |
|
RU2775692C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ADALIMUMAB | 2014 |
|
RU2664736C2 |
| LIQUID PHARMACEUTICAL COMPOSITION | 2015 |
|
RU2719431C2 |
| RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
| COMPOSITIONS OF ANTIBODIES TO RSV AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2807524C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
